Rifaximin for treatment of hepatic encephalopathy

Annals of Pharmacotherapy

Volumn 43, Issue 1, 2009, Pages 77-84

  Maclayton, Darego O ^a   Eaton Maxwell, Angie ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

Cirrhosts; Hepatic encephalopathy; Rifaximin

Indexed keywords

ALBUMIN; AMMONIA; ANTIBIOTIC AGENT; BENZODIAZEPINE; DISACCHARIDE; LACTITOL; LACTULOSE; NEOMYCIN; PAROMOMYCIN; RIFAXIMIN; SODIUM; SORBITOL; THIOL DERIVATIVE; TOXIN; GASTROINTESTINAL AGENT; RIFAMYCIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EEG ABNORMALITY; FLAPPING TREMOR; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; RIFAMYCINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 58549083121     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K436     Document Type: Review

References (33)

1. Chung RT, Podolsky DK. Cirrhosis and its complications. In: Kasper DL, Fauci AS, Longo DL, eds. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill Companies, Inc., 2005: 1858-69.
2. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-76.
3. Lizardi-Cervera J, Almeda P, Guevara L, Uribe M. Hepatic encephalopathy: a review. Ann Hepatol 2003;2:122-30.
4. Festi D, Vestito A, Mazzella G, Roda E, Colecchia A. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006;73(suppl 1):94-101.
5. Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann Hepatol 2002;1:72-9.
6. Thuluvath PJ. Higher prevalence and severity of hepatic encephalopathy in patients with HCV cirrhosis and diabetes mellitus: is presence of autonomic neuropathy the missing part of the puzzle? Am J Gastroenterol 2006;101:2244-6.
7. Wolf DC. Hepatic encephalopathy. Emedicine. www.emedicine.com/ medtopic3185.html (accessed 2007 Jun 27).
8. Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1):11-6.
9. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72:573-83.
10. Mullen KD, Jones EA. Natural benzodiazepines and hepatic encephalopathy. Semin Liver Dis 1996;16:255-64.
11. Jones EA, Basile AS. Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? Metab Brain Dis 1998;13:351-60.
12. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046. DOI 10.1136/bmj.38048.506134.EE
13. Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3:201-11.
14. Package insert. Xifaxan (rifaximin) tablets. Morrisville, NC: Salix Pharmaceuticals, January 2007.
15. Pentikis HS, Connolly M, Trapnell CB, Forbes WP, Bettenhausen DK. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007;27:1361-9.
16. Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007;41:222-8. Epub 6 Feb 2007. DOI 10.1345/aph.1H395
17. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-8.
18. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-18.
19. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993;54:598-609.
20. Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995;13:274-81.
21. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005;46:399-407.
22. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-8.
23. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003;49:53-62.
24. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-8.
25. Di Piazza S, Filippazzo MG, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991;23:403-7.
26. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997;13:593-601.
27. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006;38:3552-5.
28. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;52:737-41.
29. De Marco F, Amato PS, D'Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res 1984;36:668-74.
30. Testa R, Eftimiadi C, Sukkar GS, et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11:387-92.
31. Parini P, Cipolla A, Ronci M, et al. Effect of paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992;52:34-9.
32. RICE trial: Rifaximin In Chronic Hepatic Encephalopathy - a randomized, controlled trial. National Library of Medicine. www.clinicaltrials.gov/ct/show/ NCT00364689?order=1 (accessed 2008 Aug 3).
33. A multi-center randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety and tolerability of rifaximin 550 mg BID for 6 months in preventing hepatic encephalopathy. National Library of Medicine. www.clinicaltrials.gov/ct/show/NCT00298038?order=2 (accessed 2008 Aug 3).